hotspot -WSS

hotspot

author：focus 2025-09-29 16:45:24 - browse：4375

The experimental Alzheimer’s drug lecanemab, hailed after it slowed patients’ cognitive decline in a clinical trial, may have contributed to the death in June of a patient in the study, STAT has learned.

One investigator on the study flagged the death, noting it came after the patient experienced bleeding in the brain, and concluded it was related to the drug, according to documents obtained by STAT. Eisai, the drugmaker behind lecanemab, disagreed, pointing to other possible factors, including a series of setbacks in preceding months — multiple falls, a heart attack, a respiratory infection, and mini-stroke-like events.

Though still under investigation, the death suggests that new medicines to treat Alzheimer’s, like medicines to treat anything else, will come with their own side effects and costs. It also raises the importance of waiting for the full lecanemab data before drawing conclusions based on the positive press release put out by Eisai and its partner Biogen last month.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： In Memoriam: Notable people who died in 2023
Next article： First recipient of genetically engineered pig kidney has died

WSS

Medicare explains how it will choose drugs for negotiation

Departing Stanford president retracts two papers

Software glitch causes Tandem insulin pump to shutdown, FDA warns

AstraZeneca bets AAV gene therapy will still deliver the goods

What do new weight loss drugs mean for bariatric surgery?

Software glitch causes Tandem insulin pump to shutdown, FDA warns

focus

hotspot

leisure time

Dobbs anniversary: the lost opportunity of abortion as health care

Departing Stanford president retracts two papers

Medical leaders decry Supreme Court decision on affirmative action

It shouldn't be easy to buy synthetic DNA to recreate a deadly virus

After affirmative action ruling, medical educators look to 'holistic review'

Readout LOUD podcast: brain research, obesity drug sales, Novartis

FDA approval of Sarepta Duchenne genetic therapy gives me hope

Dairy farmers resist CDC push for PPE against bird flu virus

Hollywood unions extend contract negotiations for actors

Software glitch causes Tandem insulin pump to shutdown, FDA warns

Wikipedia

Study: AI not yet building 'n

After gene therapy, two congenitally deaf children hear for the first time

Complete sequence of Y chromosome published for first time

Radiation, mainstay of cancer treatment, begins a fade

What AAP's gender

Shionogi licenses Pompe disease therapy from Maze Therapeutics

explore

entertainment

hotspot

focus